IP Library Granted Patent US 11,549,940
Granted Patent B2
US 11,549,940 · App. 16/641,880 · Granted Jan 10, 2023

Method for detecting analyte

Inventors: Makiko Otani (Tokyo, JP); Koji Miyazaki (Hino, JP)
Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
G01N33/54306G01N33/6887
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,549,940
App. No.
16/641,880
Granted
Jan 10, 2023
Kind
B2
Abstract

A method for detecting an analyte according to the present invention includes: a first step of supplying a specimen to a detection device having a first ligand that is immobilized on a substrate and is capable of specifically binding to the analyte, the specimen being supplied onto the substrate of the detection device, and then causing the analyte included in the specimen to bind to the first ligand; a second step of supplying, onto the substrate, a second ligand that is labeled with a marker and is capable of specifically binding to the analyte, and then causing the second ligand to bind to the analyte bound to the first ligand; and a third step of measuring the second ligand bound to the analyte, wherein in the second step, carboxymethyl dextran is supplied onto the substrate.

Claims (19)

1. A method for detecting an analyte, the method comprising:

supplying a specimen to a detection device having a first ligand, the first ligand being immobilized on a substrate and capable of specifically binding to the analyte, the specimen being supplied onto the substrate of the detection device, and then causing the analyte included in the specimen to bind to the first ligand, wherein the substrate comprises a hydrophilic polymer layer, and the first ligand is directly immobilized to the hydrophilic polymer layer, and the speciment has been diluted with a solvent consisting of phosphate buffered saline, Tris buffered saline, or HEPES buffered saline;

supplying a second ligand onto the substrate, the second ligand being labeled with a marker and capable of specifically binding to the analyte, and then causing the second ligand to bind to the analyte bound to the first ligand; and

measuring the second ligand bound to the analyte,

wherein in the supplying the second ligand, carboxymethyl dextran is supplied onto the substrate, and

wherein the hydrophilic polymer layer is composed of carboxymethyl dextran.

2. The method for detecting an analyte according to claim 1 , wherein in the supplying the second ligand, carboxymethyl dextran is supplied onto the substrate at a concentration of 1 to 30 mg/mL.

3. The method for detecting an analyte according to claim 1 , wherein in the supplying the second ligand, carboxymethyl dextran is supplied onto the substrate together with the second ligand.

4. The method for detecting an analyte according to claim 3 , wherein in the supplying the second ligand, a second ligand-containing liquid containing the second ligand and carboxymethyl dextran is supplied onto the substrate.

5. The method for detecting an analyte according to claim 1 , wherein in the supplying the second ligand, the second ligand is supplied onto the substrate so as to cause the second ligand to bind to the analyte, and then carboxymethyl dextran is supplied thereonto.

6. The method for detecting an analyte according to claim 5 , wherein in the supplying the second ligand, after the second ligand is caused to bind to the analyte, carboxymethyl dextran is supplied in the form of being incorporated into a cleaning liquid for cleaning the substrate.

7. The method for detecting an analyte according to claim 1 , wherein the analyte is cardiac troponin I (cTnI) or brain natriuretic peptide (BNP).

8. The method for detecting an analyte according to claim 2 , wherein in the supplying the second ligand, carboxymethyl dextran is supplied onto the substrate together with the second ligand.

9. The method for detecting an analyte according to claim 2 , wherein in the supplying the second ligand, the second ligand is supplied onto the substrate so as to cause the second ligand to bind to the analyte, and then carboxymethyl dextran is supplied thereonto.

10. The method for detecting an analyte according to claim 2 , wherein the analyte is cardiac troponin I (cTnI) or brain natriuretic peptide (BNP).

11. The method for detecting an analyte according to claim 3 , wherein the analyte is cardiac troponin I (cTnI) or brain natriuretic peptide (BNP).

12. The method for detecting an analyte according to claim 4 , wherein the analyte is cardiac troponin I (cTnI) or brain natriuretic peptide (BNP).

13. The method for detecting an analyte according to claim 5 , wherein the analyte is cardiac troponin I (cTnI) or brain natriuretic peptide (BNP).

14. The method for detecting an analyte according to claim 6 , wherein the analyte is cardiac troponin I (cTnI) or brain natriuretic peptide (BNP).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2022
From: KONICA MINOLTA, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 059747/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2020
From: OTANI, MAKIKO; MIYAZAKI, KOJI
To: KONICA MINOLTA, INC.
Reel/Frame 052019/0091 →
Priority Claims (1)
JP JP2017-192684 · Oct 2, 2017 · national
Continuity (1)
Related Publication 20200249226A1 · Aug 6, 2020